GLP-1 derivative liraglutide in rats with β-cell deficiencies:: influence of metabolic state on β-cell mass dynamics

被引:163
作者
Sturis, J [1 ]
Gotfredsen, CF
Romer, J
Rolin, B
Ribel, U
Brand, CL
Wilken, M
Wassermann, K
Deacon, CF
Carr, RD
Knudsen, LB
机构
[1] Novo Nordisk AS, Discovery, DK-2880 Bagsvaerd, Denmark
[2] Univ Copenhagen, Panum Inst, DK-2200 Copenhagen, Denmark
关键词
glucagon-like peptide-1; type II diabetes; Zucker diabetic fatty; 60% pancreatectomy;
D O I
10.1038/sj.bjp.0705397
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Liraglutide is a long-acting GLP-1 derivative, designed for once daily administration in type II diabetic patients. To investigate the effects of liraglutide on glycemic control and beta-cell mass in rat models of beta-cell deficiencies, studies were performed in male Zucker diabetic fatty (ZDF) rats and in 60% pancreatectomized rats. 2 When liraglutide was dosed s.c. at 150 mug kg(-1) b.i.d. for 6 weeks in ZDF rats 6-8 weeks of age at study start, diabetes development was markedly attenuated. Blood glucose was approximately 12 mM lower compared to vehicle (P<0.0002), and plasma insulin was 2-3-fold higher during a normal 24-h feeding period (P<0.001). Judged by pair feeding, approximately 53% of the antihyperglycemic effect observed on 24-h glucose profiles was mediated by a reduction in food intake, which persisted throughout the study and averaged 16% (P<0.02). 3 Histological analyses revealed that beta-cell mass and proliferation were significantly lower in prediabetic animals still normoglycemic after 2 weeks treatment compared to vehicle-treated animals that had begun to develop diabetes. When the treatment period was 6 weeks, the liraglutide-treated animals were no longer completely normoglycemic and the beta-cell mass was significantly increased compared to overtly diabetic vehicle-treated animals, while beta-cell proliferation was unaffected. 4 In the experiments with 60% pancreatectomized rats, 8 days treatment with liraglutide resulted in a significantly lower glucose excursion in response to oral glucose compared to vehicle treatment. Again, part of the antihyperglycemic effect was due to reduced food intake. No effect of liraglutide on beta-cell mass was observed in these virtually normoglycemic animals. 5 In conclusion, treatment with liraglutide has marked antihyperglycemic effects in rodent models of beta-cell deficiencies, and the in vivo effect of liraglutide on beta-cell mass may in part depend on the metabolic state of the animals.
引用
收藏
页码:123 / 132
页数:10
相关论文
共 52 条
[1]   The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men [J].
Agerso, H ;
Jensen, LB ;
Elbrond, B ;
Rolan, P ;
Zdravkovic, M .
DIABETOLOGIA, 2002, 45 (02) :195-202
[2]   Unbiased estimation of total β-cell number and mean β-cell volume in rodent pancreas [J].
Bock, T ;
Svenstrup, K ;
Pakkenberg, B ;
Buschard, K .
APMIS, 1999, 107 (08) :791-799
[3]  
Bregenholt S, 2001, DIABETES, V50, pA31
[4]   Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor [J].
Burcelin, R ;
Da Costa, A ;
Drucker, D ;
Thorens, B .
DIABETES, 2001, 50 (08) :1720-1728
[5]   Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells [J].
Buteau, J ;
Roduit, R ;
Susini, S ;
Prentki, M .
DIABETOLOGIA, 1999, 42 (07) :856-864
[6]  
CLARK JB, 1983, P SOC EXP BIOL MED, V173, P68
[7]   EFFECTS OF GLUCAGON-LIKE PEPTIDE I-(7-36) ON RELEASE OF INSULIN, GLUCAGON, AND SOMATOSTATIN BY RAT PANCREATIC-ISLET CELL MONOLAYER-CULTURES [J].
DALESSIO, DA ;
FUJIMOTO, WY ;
ENSINCK, JW .
DIABETES, 1989, 38 (12) :1534-1538
[8]   DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO [J].
DEACON, CF ;
JOHNSEN, AH ;
HOLST, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :952-957
[9]   Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig [J].
Deacon, CF ;
Pridal, L ;
Klarskov, L ;
Olesen, M ;
Holst, JJ .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1996, 271 (03) :E458-E464
[10]   Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?) [J].
Edvell, A ;
Lindström, P .
ENDOCRINOLOGY, 1999, 140 (02) :778-783